Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy targets EBV-Linked cancers in early trial

NCT ID NCT07450391

Recruiting now Disease control Sponsor: Daihong Liu Source: ClinicalTrials.gov ↗

First seen Mar 11, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain lymphomas and post-transplant complications. About 18 adults will receive up to three infusions of the treatment to see if it is safe and to find the best dose. The goal is to control the disease, not necessarily cure it, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EBV-POSITIVE LYMPHOMA EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS